Scilex Taps $15.8M from Vivasor Credit Line, Paying with 50M Datavault AI Shares
SCLX has more than doubled off its 52-week low of $2.615.
Summary
Scilex drew $15.8 million from its Vivasor credit facility, paying with 50 million Datavault AI shares at $0.3151 each. The drawdown comes days after Scilex reported only $0.6 million in cash and going-concern doubts.
Key Events · Ownership and Investor Activity · SCLX
-
First Drawdown on Vivasor Credit Line
Scilex drew $15,755,000 from its $20 million revolving credit facility with Vivasor, Inc., transferring 50,000,000 shares of Datavault AI (DVLT) common stock at $0.3151 per share on August 20, 2026.
-
Near-Exhaustion of Credit Facility
The $15.8 million drawdown consumes approximately 79% of the $20 million facility, leaving roughly $4.2 million in remaining capacity.
-
Liquidity Lifeline Amid Going-Concern Doubts
The drawdown follows Scilex's August 14 10-Q reporting $0.6 million in cash, a $115 million Q2 net loss, and substantial doubt about its ability to continue as a going concern.
-
Related-Party Transaction
Vivasor, Inc. is a related party; the credit facility was disclosed in an 8-K filed August 12, 2026.
Analysis · SCLX · Life Sciences
Scilex Holding Co. drew down $15.8 million from its $20 million revolving credit facility with Vivasor, Inc., transferring 50 million shares of Datavault AI (DVLT) common stock at $0.3151 per share as payment. This is the first quantified drawdown under the facility disclosed on August 12, 2026. The transaction provides Scilex with liquidity at a critical time — the company reported just $0.6 million in cash and a $115 million Q2 net loss on August 14, with substantial doubt about its ability to continue as a going concern. The drawdown nearly exhausts the credit line, leaving limited remaining capacity.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 29.4% of the 2796 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.03%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SCLX was trading at $5.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $48.1M. The 52-week trading range was $2.62 to $21.34. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.